ストックスクリーナーアプリを入手
1.02
2.00%
0.02
アフターアワーズ：
1.01
-0.01
-0.98%
Ocugen Inc (OCGN) 最新ニュース
3rd Circ. Topples Materiality Rule For Securities Suits - Law360
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen, Inc. (OCGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ocugen Row Revived as Third Cir. Dumps Investor Materiality Rule - Bloomberg Law News
A gene therapy poster will report three-year vision benefits across mutations - Stock Titan
Enterprise value to EBIT forward of Ocugen Inc – HAN:2H51 - TradingView
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen Inc Earnings and Revenue – HAN:2H51 - TradingView
Ocugen Inc Revenue Breakdown – HAN:2H51 - TradingView
Analysts Conflicted on These Healthcare Names: Ocugen (OCGN), Aveanna Healthcare Holdings (AVAH) and Universal Health (UHS) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN) - The Globe and Mail
Ocugen to Participate in Upcoming October Investor and Industry Conferences - GlobeNewswire
H.C. Wainwright raises Ocugen stock price target on Bahamas approval By Investing.com - Investing.com Nigeria
What's Behind Ocugen's (NASDAQ:OCGN) Big Moment in Healthcare Stocks? - kalkinemedia.com
H.C. Wainwright raises Ocugen stock price target on Bahamas approval - Investing.com
Ocugen's Retina Data Impress, but a 250 Million Share Vote Still Holds the Reins - AD HOC NEWS
Ocugen's Island Approval Arrives as a 250 Million Share Decision Waits in the Wings - AD HOC NEWS
Ocugen's Bahamian Green Light Meets a Shareholder Reckoning - AD HOC NEWS
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen receives provisional approval for gene therapy in Bahamas By Investing.com - Investing.com Nigeria
Ocugen Wins Bahamas Priority Path for OCU400 Gene Therapy - MyChesCo
Ocugen Receives OCU400 Priority Designation in Bahamas - grafa.com
Why Is OCGN Stock Rising Today? - stocktwits.com
Ocugen Gets Provisional Approval for OCU400 in Bahamas - marketscreener.com
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days - Yahoo Finance
Ocugen's 32% Lesion Slowdown Meets a Balance Sheet That Won't Wait - AD HOC NEWS
OCGN Looks 22.0% Overvalued on GF Value™ - GuruFocus
Ocugen receives provisional approval for gene therapy in Bahamas - Investing.com
Ocugen Announces Expanded Access Program for OCU400 in Retinitis Pigmentosa Following LARTA Provisional Approval - quiverquant.com
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa - Ocugen, Inc.
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen (OCGN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Ocugen stockholders approve adjournment of special meeting for share increase vote - Investing.com Nigeria
Why Is Ocugen (NASDAQ:OCGN) Back in Focus as Wall Street Balances Growth and Defensive Demand? - Kalkine Media
Form 8K Ocugen, Inc For: 23 September By Investing.com - Investing.com Australia
Form 8K Ocugen, Inc For: 23 September - Investing.com India
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $9.5 - Moomoo
OCGN: Proposal to increase authorized shares delayed due to insufficient votes; adjournment approved - TradingView
OCGN: Proposal to increase authorized shares stalled; adjourned meeting set for further voting - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances - TradingView
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
OCGN Stock Slips As Traders Focus On Weak Financials - StocksToTrade
OCGN Stock Slips As Weak Financials Weigh On Momentum - timothysykes.com
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts (OCGN) - Seeking Alpha
What's Happening With Ocugen Stock Thursday? - TradingView
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com India
OCGN Maintains Buy by HC Wainwright & Co. -- Price Target Lowered to $9.50 - GuruFocus
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):